Compare Incyte Corporation (INCY) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MPLX LP — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while MPLX LP trades at $56.3 (market cap $58.11B). The key difference: MPLX LP is far larger — about 2.5× Incyte Corporation's market cap, and MPLX LP pays a 7.51% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MPLX | |
|---|---|---|
Market Cap | $22.85B | $58.11B |
Volume | 1,927,029 | 687,483 |
Sector | Health | Energy |
52-Week High | $129.93 | $60.51 |
52-Week Low | $83.80 | $47.80 |
Typical Hold Time | 33 Days | — |
Enterprise Value | $18.35B | $83.22B |
Dividend Yield | — | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
MPLX trades at $57.32, up 0.47% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, supported by $4.91B net income in 2025. Recent earnings show mixed results with a Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 11.3% upside potential.
The investment case balances strong cash flow generation and dividend stability against energy market volatility risks. MPLX's fee-based midstream model provides revenue resilience, though technical indicators suggest near-term pressure. The 67.86% buy rating consensus indicates Wall Street confidence in the company's ability to maintain distribution growth despite recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
